Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45
Purified protein vaccines often require adjuvants for efficient stimulation of immune responses. There is no licensed mucosal adjuvant on the market to adequately boost the immune response to purified antigens for intranasal applications in humans. Bacterial outer membrane vesicles (OMV) are attract...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/3576028 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563980213682176 |
|---|---|
| author | Michael Pritsch Najib Ben-Khaled Michael Chaloupka Sebastian Kobold Nicole Berens-Riha Annabell Peter Gabriele Liegl Sören Schubert Michael Hoelscher Thomas Löscher Andreas Wieser |
| author_facet | Michael Pritsch Najib Ben-Khaled Michael Chaloupka Sebastian Kobold Nicole Berens-Riha Annabell Peter Gabriele Liegl Sören Schubert Michael Hoelscher Thomas Löscher Andreas Wieser |
| author_sort | Michael Pritsch |
| collection | DOAJ |
| description | Purified protein vaccines often require adjuvants for efficient stimulation of immune responses. There is no licensed mucosal adjuvant on the market to adequately boost the immune response to purified antigens for intranasal applications in humans. Bacterial outer membrane vesicles (OMV) are attractive candidates potentially combining antigenic and adjuvant properties in one substance. To more precisely characterize the potential of Escherichia coli OMV for intranasal vaccination with heterologous antigens, immune responses for AnAPN1 and Pfs48/45 as well as ovalbumin as a reference antigen were assessed in mice. The intranasal adjuvant cholera toxin (CT) and parenteral adjuvant MF59C.1 were used in comparison. Vaccinations were administered intranasally or subcutaneously. Antibodies (total IgG and IgM as well as subclasses IgG1, IgG2a, IgG2b, and IgG3) were measured by ELISA. T cell responses (cytotoxic T cells, Th1, Th17, and regulatory T cells) were determined by flow cytometry. When OMV were used as adjuvant for intranasal immunization, antibody and cellular responses against all three antigens could be induced, comparable to cholera toxin and MF59C.1. Antigen-specific IgG titres above 1 : 105 could be detected in all groups. This study provides the rationale for further development of OMV as a vaccination strategy in malaria and other diseases. |
| format | Article |
| id | doaj-art-38210bb2bf1d48018aa520174d6e8bee |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-38210bb2bf1d48018aa520174d6e8bee2025-02-03T01:12:08ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/35760283576028Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45Michael Pritsch0Najib Ben-Khaled1Michael Chaloupka2Sebastian Kobold3Nicole Berens-Riha4Annabell Peter5Gabriele Liegl6Sören Schubert7Michael Hoelscher8Thomas Löscher9Andreas Wieser10Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Internal Medicine IV, University of Munich (LMU), 80337 Munich, GermanyCenter of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Internal Medicine IV, University of Munich (LMU), 80337 Munich, GermanyDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyDepartment of Bacteriology, Max von Pettenkofer Institute (LMU), 81337 Munich, GermanyDepartment of Bacteriology, Max von Pettenkofer Institute (LMU), 81337 Munich, GermanyDepartment of Bacteriology, Max von Pettenkofer Institute (LMU), 81337 Munich, GermanyDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyDivision of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), 80802 Munich, GermanyPurified protein vaccines often require adjuvants for efficient stimulation of immune responses. There is no licensed mucosal adjuvant on the market to adequately boost the immune response to purified antigens for intranasal applications in humans. Bacterial outer membrane vesicles (OMV) are attractive candidates potentially combining antigenic and adjuvant properties in one substance. To more precisely characterize the potential of Escherichia coli OMV for intranasal vaccination with heterologous antigens, immune responses for AnAPN1 and Pfs48/45 as well as ovalbumin as a reference antigen were assessed in mice. The intranasal adjuvant cholera toxin (CT) and parenteral adjuvant MF59C.1 were used in comparison. Vaccinations were administered intranasally or subcutaneously. Antibodies (total IgG and IgM as well as subclasses IgG1, IgG2a, IgG2b, and IgG3) were measured by ELISA. T cell responses (cytotoxic T cells, Th1, Th17, and regulatory T cells) were determined by flow cytometry. When OMV were used as adjuvant for intranasal immunization, antibody and cellular responses against all three antigens could be induced, comparable to cholera toxin and MF59C.1. Antigen-specific IgG titres above 1 : 105 could be detected in all groups. This study provides the rationale for further development of OMV as a vaccination strategy in malaria and other diseases.http://dx.doi.org/10.1155/2016/3576028 |
| spellingShingle | Michael Pritsch Najib Ben-Khaled Michael Chaloupka Sebastian Kobold Nicole Berens-Riha Annabell Peter Gabriele Liegl Sören Schubert Michael Hoelscher Thomas Löscher Andreas Wieser Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 Journal of Immunology Research |
| title | Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 |
| title_full | Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 |
| title_fullStr | Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 |
| title_full_unstemmed | Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 |
| title_short | Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45 |
| title_sort | comparison of intranasal outer membrane vesicles with cholera toxin and injected mf59c 1 as adjuvants for malaria transmission blocking antigens anapn1 and pfs48 45 |
| url | http://dx.doi.org/10.1155/2016/3576028 |
| work_keys_str_mv | AT michaelpritsch comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT najibbenkhaled comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT michaelchaloupka comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT sebastiankobold comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT nicoleberensriha comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT annabellpeter comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT gabrieleliegl comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT sorenschubert comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT michaelhoelscher comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT thomasloscher comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 AT andreaswieser comparisonofintranasaloutermembranevesicleswithcholeratoxinandinjectedmf59c1asadjuvantsformalariatransmissionblockingantigensanapn1andpfs4845 |